Immunovant is currently investigating therapies for people with myasthenia gravis (MG), thyroid eye disease (TED), and warm autoimmune hemolytic anemia (WAIHA).
We intend to develop IMVT-1401 as a fixed-dose subcutaneous injection to be administered at home.
Summary information about our ongoing trials is provided below. For more information, please visit www.clinicaltrials.gov
A Study of RVT-1401 in Myasthenia Gravis (MG) Patients
Brief Summary: The purpose of the current study is to assess safety/tolerability and key pharmacodynamic (PD) effects that are considered to be associated with clinical benefit (reduction of total IgG and anti-AChR-IgG) in MG patients following treatment with RVT-1401 (currently known as IMVT-1401) compared to placebo.
Estimated Enrollment: 21 participants
Study Start Date: May 21, 2019
A Study of RVT-1401 for the Treatment of Patients With Moderate to Severe Active Thyroid Eye Disease (TED)
Brief Summary: The purpose of the current study is to confirm safety/tolerability and key pharmacodynamic (PD) effects that are considered to drive clinical benefit in TED patients.
Estimated Enrollment: 8 participants
Study Start Date: April 22, 2019
A Study of RVT-1401 for the Treatment of Patients with Active, Moderate to Severe Thyroid Eye Disease (TED)
Brief Summary: The purpose of the current study is to assess the efficacy and safety/tolerability of three dose regimens of RVT-1401 (currently known as IMVT-1401) in the treatment of active, moderate to severe TED patients. In addition, the study is designed to characterize the effect of RVT-1401 exposure on reduction in anti-TSHR IgG.
Estimated Enrollment: 77 participants
Study Start Date: July 23, 2019
To learn more visit our TED study website at https://ascendtedstudy.com/
If you would like to learn more about our clinical trials, please contact firstname.lastname@example.org